Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 21 04:00PM ET
2.23
Dollar change
-0.06
Percentage change
-2.40
%
Index- P/E- EPS (ttm)-0.07 Insider Own2.46% Shs Outstand5.45M Perf Week2.76%
Market Cap12.18M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float5.31M Perf Month-20.18%
Income-0.38M PEG- EPS next Q- Inst Own4.75% Short Float0.41% Perf Quarter-7.64%
Sales0.00M P/S- EPS this Y- Inst Trans-0.81% Short Ratio0.04 Perf Half Y125.76%
Book/sh0.50 P/B4.50 EPS next Y- ROA-12.10% Short Interest0.02M Perf Year75.98%
Cash/sh0.43 P/C5.21 EPS next 5Y- ROE-13.07% 52W Range0.75 - 4.99 Perf YTD121.27%
Dividend Est.- P/FCF- EPS past 5Y- ROI-13.97% 52W High-55.21% Beta1.20
Dividend TTM- Quick Ratio11.43 Sales past 5Y0.00% Gross Margin- 52W Low198.00% ATR (14)0.24
Dividend Ex-Date- Current Ratio11.43 EPS Y/Y TTM86.44% Oper. Margin0.00% RSI (14)44.34 Volatility10.21% 9.34%
Employees8 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price6.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q152.66% Payout- Rel Volume0.00 Prev Close2.29
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume516.98K Price2.23
SMA20-7.61% SMA50-11.24% SMA20052.85% Trades Volume2,363 Change-2.40%
Date Action Analyst Rating Change Price Target Change
May-08-15Initiated H.C. Wainwright Buy $6
Jun-17-24 07:40AM
Jun-05-24 09:15AM
May-13-24 07:23AM
Apr-29-24 07:33AM
Mar-20-24 10:15AM
04:00PM Loading…
Oct-20-23 04:00PM
04:00PM
Nov-21-18 08:00AM
Nov-01-18 10:09AM
Jul-24-18 09:09AM
May-29-18 05:37PM
Dec-13-17 07:30AM
Dec-06-17 12:08PM
Nov-27-17 10:30AM
Oct-23-17 11:23AM
07:30AM Loading…
Oct-06-17 07:30AM
Oct-05-17 07:50AM
Sep-26-17 09:23AM
Sep-12-17 09:00AM
Jul-11-17 07:00AM
Jun-15-17 09:00AM
Apr-27-17 09:50AM
Apr-05-17 09:10AM
Mar-30-17 08:55AM
Mar-22-17 09:22AM
Mar-07-17 12:40PM
Mar-01-17 08:30AM
Feb-17-17 08:00AM
Feb-13-17 09:08AM
Jan-25-17 08:30AM
08:30AM Loading…
Jan-05-17 08:30AM
Dec-19-16 08:00AM
Dec-06-16 08:30AM
Nov-09-16 01:25PM
Sep-27-16 08:30AM
Sep-07-16 08:32AM
Sep-06-16 08:00AM
Aug-11-16 09:00AM
Jun-02-16 09:11AM
Jun-01-16 08:30AM
May-16-16 11:45AM
Apr-07-16 01:04PM
Mar-31-16 09:45AM
Mar-21-16 08:30AM
Mar-09-16 08:29AM
Mar-02-16 09:00AM
Feb-22-16 09:02AM
Feb-10-16 08:30AM
Jan-27-16 08:30AM
Jan-25-16 08:30AM
Jan-13-16 08:30AM
Jan-11-16 08:30AM
Dec-01-15 08:30AM
Nov-09-15 08:30AM
Oct-28-15 09:00AM
Oct-26-15 09:15AM
Oct-13-15 08:45AM
Sep-17-15 11:40AM
Sep-03-15 09:00AM
Sep-01-15 09:00AM
Aug-26-15 09:00AM
Jun-01-15 08:00AM
May-11-15 10:50AM
May-09-15 09:45AM
May-08-15 09:35AM
07:43AM
Apr-28-15 07:45AM
Mar-31-15 09:30AM
Feb-17-15 08:30AM
Dec-30-14 12:23PM
Dec-08-14 08:30AM
Dec-01-14 08:00AM
Sep-02-14 12:09PM
Jul-22-14 02:54PM
Jul-16-14 09:18AM
Jun-12-14 08:00AM
Jun-02-14 09:00AM
May-19-14 08:00AM
Apr-02-14 04:41PM
Mar-25-14 08:00AM
Jan-08-14 08:00AM
XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its product pipeline includes hCDR1 and rHuEPO. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.